Novel treatment approaches for patients with multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 6, Issue 4, 2006, Pages 281-288

  Sinha, Rajni ^a   Kaufman, Jonathan L ^a   Lonial, Sagar ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Lenalidomide; Proteasome inhibition; Targeted theraphy; Thalidomide

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ANTHRACYCLINE; ATIPRIMOD; BORTEZOMIB; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PERIFOSINE; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; SELECTIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TIPIFARNIB; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; ANGIOGENESIS INHIBITOR; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; HEAT SHOCK PROTEIN; HISTONE; ONCOPROTEIN; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROTECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DISEASE DURATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INFECTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; SURVIVAL TIME; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; METABOLISM; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN PROCESSING; RECURRENT DISEASE; REMISSION; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; BORONIC ACIDS; CELL PROLIFERATION; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HEAT-SHOCK PROTEINS; HISTONES; HUMANS; MULTIPLE MYELOMA; ONCOGENE PROTEIN V-AKT; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZINES; RECURRENCE; REMISSION INDUCTION; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 33645066665     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.002     Document Type: Review

References (70)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:91-97.
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
3. Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104:607-618.
4. Lenz W. Thalidomide and congenital abnormalities. Lancet 1962; 1:45.
5. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994; 87:503-508.
6. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angigenesis. Proc Natl Acad Sci U S A 1994; 91-4082-4085.
7. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 67:971-978.
8. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
9. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98:492-494.
10. Alexanian R, Webes D. Thalidomide for resistant and relapsing myeloma. Semin Hematol 2000; 37:22-25.
11. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75:897-901.
12. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86:404-408.
13. Tosi P, Cavo M. Thalidomide in multiple myeloma: state of art. Haematologica 2002; 87:233-234.
14. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12:991-995.
15. Weber D, Rankin K, Gavino M, et al. Thalidomide with dexamethasone for resistant multiple myeloma. Blood 2000; 97:167a.
16. Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121:768-771.
17. Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, et al. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J 2002; 3:43-48.
18. Dimopoulos MA, Hamilos G, Zomas A. et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5:112-117.
19. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21:2732-2739.
20. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4:314-322.
21. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210-216.
22. Lentzsh S, Le Blanc R, Podar K, et al. Immunomodulatory derivatives of thalidomide inhibit growth of B-cell hematologic malignancies and angiogenesis in vivo. Leukemia 2003; 17:41-44.
23. Richardson P, Schlossman R. Hideshima T. et al. A phase 1 study of oral CC5013, an immunomodulatory thalidomide (thal) derivative in patients with relapsed and refractory multiple myeloma (MM). Blood 2002: 99:4525-4530.
24. Richardson P, Jagannath S. Schlossman R, et al. A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CC-5013 dose regimens when used alone or in combination with dexamethasone (dex) for the treatment of relapsed or refractory multiple myeloma (MM). Blood 2003; 102:235a.
25. Richardson P, Jagganath S, Hussein MA, et al. A multicenter, single arm, open label study to evaluate the safety and efficacy of single agent lenalidomide in subjects with relasped and refractory multiple myeloma. Blood 2005; 106:1565.
26. Weber D. Lenalidomide (CC-5013, Revlimid) and other IMIDS. Haematologica 2005; 90:24.
27. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22:3269-3276.
28. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4:349-360.
29. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076.
30. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20:4420-4427.
31. Richardson PG, Barlogie B, Berenson. J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
32. Richardson P, Schlossman R. Hideshima T. et al. A phase 1 study of oral CC5013, an immunomodulatory thalidomide (thal) derivative in patients with relapsed and refractory multiple myeloma (MM). Blood 2002: 99:4525-4530.
33. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498.
34. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101:2377-2380.
35. Richardson P, Schlossman R. Hideshima T. et al. A phase 1 study of oral CC5013, an immunomodulatory thalidomide (thal) derivative in patients with relapsed and refractory multiple myeloma (MM). Blood 2002: 99:4525-4530.
36. Zangari M, Barlogie B, Hollmig K, et al. Marked activity of velcade plus thalidomide in advanced and refractory multiple myeloma. Blood 2004; 104:413a (Abstract #1480).
37. Berenson J, Yang H, Swift RA. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/ II study. Blood 2004; 104:64a (Abstract #209).
38. Chanan-Khan A, Miller K. Velcade, Doxil and thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leuk Lymphoma 2005; 46:1103-1104.
39. Yang HH, Vescio R, Schenkein D, et al. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, Velcadetrade mark) and melphalan in patients with relapsed or refractory multiple myeloma. Clin Lymphoma 2003; 4:119-122.
40. Richardson P. Schlossman R, Munshi N, et al. Phase I study of the safety and efficacy of bortezomib (Velcade) in combination with CC-5013 (Revlimid) in relapsed and refractory multiple myeloma (MM): the RevVel trial. Haematologica 2005; 90(suppl 1):26.
41. Hideshima T, Podar K, Chauhan D, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004; 23:8766-8776.
42. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004; 103:3271-3277.
43. David E, Kaufman J, Sun SY, et al. The Combination of tipifarnib and bortezomib results in synergistic myeloma cell death via downregulation of phospho-AKT and induction of apoptosis. Presented at: The 10th International Myeloma Workshop; April 10-14, 2005; Sydney, Australia.
44. David E, Sinha R, Torre C, et al. Combination of farnesyl transferase inhibitor (tipifarnib) with perifosine induces apoptosis through phos-PDK1 in human lymphoma and leukemia cell lines. Blood 2005; 106:1488a.
45. Mitsiades C, Mitsiades N, Rooney M, et al. Anti-tumor activity of KOS-953, a cremophor-based formulation of the Hsp90 inhibitor 17-AAG. Blood 2004; 104:660a (Abstract #2404).
46. Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003; 63:6174-6177.
47. Rajkumar S, Blood E, Vesole D, et al. Thalidomide plus dexamethasone versus dexamethasonealone in newly diagnosed multiple myeloma (E1A00): results of a phase III trial coordinated by the Eastern Cooperative Oncology Group. Blood 2004; 104:63a (Abstract #205).
48. Palumbo A, Bertola A, Musto P, et al. A prospective randomised trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prenisone (MP): an interim analysis. Blood 2004; 104:63a (Abstract #207).
49. Facon T, Mary J, Hulin C, et al. Randomised clinical trial comparing melphalan-prednisone (MP), MP-thalidomide (MP-THAL) and high dose therapy using melphalan 100 MG/M2 (MEL100) for newly diagnosed myeloma patients aged 65-75 years. Interim analysis of the IFM 99-06 trial on 350 patients. Blood 2004; 104:63a (Abstract #206).
50. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood 2005; 106:4050-4053.
51. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2005.
52. Rajkumar S, Dingli D, Nowakowski G, et al. Thalidomide and dexamethasone in newly diagnosed multiple myeloma: Long-term results in patients not undergoing upfront autologous stem cell transplantation. Proc Am Soc Clin Oncol 2005; 24:5935 (Abstract #6632).
53. Wang M, Weber DM, Delasalle K, et al. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005; 79:194-197.
54. Palumbo A, Bertola, A, Musto P, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 2005; 104:1428-1433.
55. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783.
56. Harousseau J, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. Blood 2004; 104:416a (Abstract #1490).
57. Richardson P, Chanan-Khan A, Schlossman R, et al. Phase II trial of single agent bortezomib (Velcade) in patients with previously untreated multiple myeloma. Blood 2004; 104:100a (Abstract #336).
58. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/ bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755-762.
59. Mateos MV, Blade J, Mediavilla JD, et al. A phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients. Blood 2005; 106:232a (Abstract #786).
60. Chanan-Khan A. Niesvisky R, Hohl RJ, et al. Randomized multicenter Phase III trial of high-dose dexamethsone (dex) with or without oblimersen sodium (G3139; Bcl-2 antisense; Genasense) for patients with advanced multiple myeloma (MM). Blood 2004; 104:413a (Abstract #1477).
61. Chauhan D, Li G, Podar K, et al. Mitochondria and Caspase-independent cell death triggered GCS-100, a novel carbohydrate-based therapeutic in multiple myeloma (MM) cells. Blood 2004; 104:674a (Abstract #2456).
62. Cotter FE. SB, Carbo M, et al. GCS-100, a galectin 3 antagonist, is a novel caspase-9 apoptosis activating agent in the treatment of indolent B-cell malignancies. Blood 2004; 104:898a (Abstract #3286).
63. Hu L, Shi Y, Hsu JH, et al. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101:3126-3135.
64. Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004; 104:4188-4193.
65. Amit-Vazina M, Shishodia S, Harris D, et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma. cells. Br J Cancer 2005; 93:70-80.
66. Van Ummersen L, Binger K, Volkman J, et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004; 10:7450-7456.
67. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401:188-193.
68. Kelly WK, Richon VM, Curley T, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamicacid (SAHA), orally administered has good bioavailibility and biologic activity Proc Am Soc Clin Oncol 2002; 21:66 (Abstract #1831).
69. Kelly W, O'Connor O, Richon VM, et al. A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Eur J Cancer 2002; 38(suppl 7):88 (Abstract #286).
70. Tai YT, Catley LP, Mitsiades CS, et al. Mechanisms by which SGN-40, a humanized and-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004; 64:2846-2852.